

Publications

Articles (peer-reviewed and indexed journals)

Del Rosso JQ. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. *J Clin Aesthet Dermatol.* 2014 Jul;7(7):10-8.

Del Rosso JQ, Kircik LH. Transitioning from brand to generic with topical products and the importance of maintaining the formulation and therapeutic profiles of the original product: focus on clococtolone pivalate 0.1% cream. *J Drugs Dermatol.* 2014 Jul;13(7):s77-83.

Levin J, Fallon Friedlander S, Del Rosso JQ. Atopic dermatitis and the stratum corneum: part 3: the immune system in atopic dermatitis. *J Clin Aesthet Dermatol.* 2013 Dec;6(12):37-44.

Levin J, Friedlander SF, Del Rosso JQ. Atopic dermatitis and the stratum corneum: part 2: other structural and functional characteristics of the stratum corneum barrier in atopic skin. *J Clin Aesthet Dermatol.* 2013 Nov;6(11):49-54.

Levin J, Friedlander SF, Del Rosso JQ. Atopic dermatitis and the stratum corneum: part 1: the role of filaggrin in the stratum corneum barrier and atopic skin. *J Clin Aesthet Dermatol.* 2013 Oct;6(10):16-22.

Del Rosso JQ, Brandt S, The role of skin care as an integral component in the management of acne vulgaris: part 2: tolerability and performance of a designated skin care regimen using a foam wash and moisturizer SPF 30 in patients with acne vulgaris undergoing active treatment. *J Clin Aesthet Dermatol.* 2013 Dec;6(12):28-36.

Del Rosso JQ. The role of skin care as an integral component in the management of acne vulgaris: part 1: the importance of cleanser and moisturizer ingredients, design, and product selection. *J Clin Aesthet Dermatol.* 2013 Dec;6(12):19-27.

Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield LF, Stein-Gold L, Berson D, Zaenglein A. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. *Cutis.* 2014 Mar;93(3):134-8.

Tanghetti E, Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Eichenfield LF, Stein-Gold L, Berson D, Zaenglein A. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 4: a status report on physical modalities and devices. *Cutis.* 2014 Feb;93(2):71-6.

Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield LF, Stein-Gold L, Berson D, Zaenglein A. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. *Cutis.* 2014 Jan;93(1):18-28.

Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield LF, Stein-Gold L, Berson D, Zaenglein A. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. *Cutis.* 2013 Dec;92(6):277-84

Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield LF, Stein-Gold L, Berson D, Zaenglein A. Consensus recommendations from the American Acne & Rosacea Society on the

management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. *Cutis*. 2013 Nov;92(5):234-40.

Leyden JJ, Del Rosso JQ, Baum EW. The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions. *J Clin Aesthet Dermatol*. 2014 Feb;7(2 Suppl):S3-S21.

Del Rosso JQ, Plattner JJ. From the Test Tube to the Treatment Room: Fundamentals of Boron-containing Compounds and their Relevance to Dermatology. *J Clin Aesthet Dermatol*. 2014 Feb;7(2):13-21.

Del Rosso JQ. Incorporation of a barrier protection cream in the management of chronic hand dermatitis: focus on data supporting an established hand protectant formulation and modifications designed to assist in barrier repair. *J Clin Aesthet Dermatol*. 2014 Feb;7(2):40-8.

Del Rosso JQ, Zeichner J. What's New in the Medicine Cabinet?: A Panoramic Review of Clinically Relevant Information for the Busy Dermatologist. *J Clin Aesthet Dermatol*. 2014 Jan;7(1):26-30.

Two AM, Del Rosso JQ. Kallikrein 5-mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit. *J Clin Aesthet Dermatol*. 2014 Jan;7(1):20-5.

Del Rosso JQ, Kircik LH. Optimizing topical antifungal therapy for superficial cutaneous fungal infections: focus on topical naftifine for cutaneous dermatophytosis. *J Drugs Dermatol*. 2013 Nov;12(11 Suppl):s165-71.

Del Rosso JQ, Cash K. Topical corticosteroid application and the structural and functional integrity of the epidermal barrier. *J Clin Aesthet Dermatol*. 2013 Nov;6(11):20-7.

Kircik L, Lebwohl MG, Del Rosso JQ, Bagel J, Stein Gold L, Weiss JS. Clinical study results of desoximetasone spray, 0.25% in moderate to severe plaque psoriasis. *J Drugs Dermatol*. 2013 Dec;12(12):1404-10.

Del Rosso JQ. Management of facial erythema of rosacea: what is the role of topical α -adrenergic receptor agonist therapy? *J Am Acad Dermatol*. 2013 Dec;69(6 Suppl 1):S44-56.

Del Rosso JQ, Kircik LH. The sequence of inflammation, relevant biomarkers, and the pathogenesis of acne vulgaris: what does recent research show and what does it mean to the clinician? *J Drugs Dermatol*. 2013 Aug;12(8 Suppl):s109-15.

Lebwohl MG, Del Rosso JQ, Abramovits W, Berman B, Cohen DE, Guttman E, Mancini AJ, Schachner LA. Pathways to managing atopic dermatitis: consensus from the experts. *J Clin Aesthet Dermatol*. 2013 Jul;6(7 Suppl):S2-S18.

Del Rosso JQ, Kircik LH. The integration of physiologically-targeted skin care in the management of atopic dermatitis: focus on the use of a cleanser and moisturizer system incorporating a ceramide precursor, filaggrin degradation products, and specific "skin-barrier-friendly" excipients. *J Drugs Dermatol*. 2013 Jul 1;12(7):s85-91.

Del Rosso JQ. Application of protease technology in dermatology: rationale for incorporation into skin care with initial observations on formulations designed for skin cleansing, maintenance of hydration, and restoration of the epidermal permeability barrier. *J Clin Aesthet Dermatol*. 2013 Jun;6(6):14-22.

Coda AB, Hata T, Miller J, Audish D, Kotol P, Two A, Shafiq F, Yamasaki K, Harper JC, Del Rosso JQ, Gallo RL. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. *J Am Acad Dermatol*. 2013 Oct;69(4):570-7.

Del Rosso JQ. Clinical relevance of skin barrier changes associated with the use of oral isotretinoin: the importance of barrier repair therapy in patient management. *J Drugs Dermatol*. 2013 Jun 1;12(6):626-31.

Del Rosso JQ, Gallo RL, Tanghetti E, Webster G, Thiboutot D. An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. *Cutis*. 2013 Mar;91(3 Suppl):1-8.

Del Rosso JQ, Reece B, Smith K, Miller T. Efinaconazole 10% solution: a new topical treatment for onychomycosis: contact sensitization and skin irritation potential. *J Clin Aesthet Dermatol*. 2013 Mar;6(3):20-4.

Del Rosso JQ, Tanghetti E. A status report on topical tazarotene in the management of acne vulgaris. *J Drugs Dermatol*. 2013 Mar;12(3):s53-8.

Kim GK, Del Rosso JQ. Topical pimecrolimus 1% cream in the treatment of seborrheic dermatitis. *J Clin Aesthet Dermatol*. 2013 Feb;6(2):29-35.

Thiboutot D, Del Rosso JQ. Acne vulgaris and the epidermal barrier: Is acne vulgaris associated with inherent epidermal abnormalities that cause impairment of barrier functions? Do any topical acne therapies alter the structural and/or functional integrity of the epidermal barrier? *J Clin Aesthet Dermatol*. 2013 Feb;6(2):18-24.

Del Rosso JQ, Kircik LH. The role of a midpotency topical corticosteroid and the clinical relevance of formulation characteristics in the management of commonly encountered eczematous and inflammatory dermatoses in adults and children: focus on the pharmacologic properties of clocortolone pivalate 0.1% cream. *J Drugs Dermatol*. 2013 Feb;12(2):s5-s10.

Winkelmann RR, Kim GK, Del Rosso JQ. Treatment of cutaneous lupus erythematosus: review and assessment of treatment benefits based on Oxford Centre for Evidence-based Medicine Criteria. *J Clin Aesthet Dermatol*. 2013 Jan;6(1):27-38.

Del Rosso JQ, Kircik LH. Not all topical corticosteroids are created equal! optimizing therapeutic outcomes through better understanding of vehicle formulations, compound selection, and methods of application. *J Drugs Dermatol*. 2012 Dec;11(12):s5-8.

Del Rosso JQ. Face to face with oral isotretinoin: a closer look at the spectrum of therapeutic outcomes and why some patients need repeated courses. *J Clin Aesthet Dermatol*. 2012 Nov;5(11):17-24.

Kircik LH, Del Rosso JQ. The treatment of inflammatory facial dermatoses with topical corticosteroids: focus on clocortolone pivalate 0.1% cream. *J Drugs Dermatol*. 2012 Oct;11(10):1194-8.

Del Rosso JQ, Kircik L. A comprehensive review of clocortolone pivalate 0.1% cream: structural development, formulation characteristics, and studies supporting treatment of corticosteroid-responsive dermatoses. *J Clin Aesthet Dermatol.* 2012 Jul;5(7):20-4.

Tan J, Wolfe B, Weiss J, Stein-Gold L, Bikowski J, Del Rosso J, Webster GF, Lucky A, Thiboutot D, Wilkin J, Leyden J, Chren MM. Acne severity grading: determining essential clinical components and features using a Delphi consensus. *J Am Acad Dermatol.* 2012 Aug;67(2):187-93.

Bhatia ND, Del Rosso JQ. Optimal management of papulopustular rosacea: rationale for combination therapy. *J Drugs Dermatol.* 2012 Jul;11(7):838-44.

Leyden JJ, Del Rosso JQ. The effect of benzoyl peroxide 9.8% emollient foam on reduction of *Propionibacterium acnes* on the back using a short contact therapy approach. *J Drugs Dermatol.* 2012 Jul;11(7):830-3.

Del Rosso JQ, Preston NJ, Caveney SW, Gottschalk RW. Effectiveness and safety of modified-release doxycycline capsules once daily for papulopustular rosacea monotherapy results from a large community-based trial in subgroups based on gender. *J Drugs Dermatol.* 2012 Jun;11(6):703-7.

Del Rosso JQ, Gallo RL, Kircik L, Thiboutot D, Baldwin HE, Cohen D. Why is rosacea considered to be an inflammatory disorder? The primary role, clinical relevance, and therapeutic correlations of abnormal innate immune response in rosacea-prone skin. *J Drugs Dermatol.* 2012 Jun;11(6):694-700.

Kim GK, Del Rosso JQ. Oral spironolactone in post-teenage female patients with acne vulgaris: practical considerations for the clinician based on current data and clinical experience. *J Clin Aesthet Dermatol.* 2012 Mar;5(3):37-50.

Del Rosso JQ. Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea. *J Clin Aesthet Dermatol.* 2012 Mar;5(3):26-36.

Del Rosso JQ. Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. *J Clin Aesthet Dermatol.* 2012 Mar;5(3):16-25.

Michaels BD, Del Rosso JQ. Tinea capitis in infants: recognition, evaluation, and management suggestions. *J Clin Aesthet Dermatol.* 2012 Feb;5(2):49-59.

Del Rosso JQ, Harper J, Pillai R, Moore R. Tretinoin photostability: comparison of micronized tretinoin (0.05%) gel and tretinoin (0.025%) gel following exposure to ultraviolet a light. *J Clin Aesthet Dermatol.* 2012 Jan;5(1):27-9.

Kircik LH, Del Rosso JQ. Nonsteroidal treatment of atopic dermatitis in pediatric patients with a ceramide-dominant topical emulsion formulated with an optimized ratio of physiological lipids. *J Clin Aesthet Dermatol.* 2011 Dec;4(12):25-31.

Del Rosso JQ, Levin J. Clinical relevance of maintaining the structural and functional integrity of the stratum corneum: why is it important to you? *J Drugs Dermatol.* 2011 Oct;10(10 Suppl):s5-12.

Park H, Del Rosso JQ. Use of oral isotretinoin in the management of rosacea. *J Clin Aesthet Dermatol.* 2011 Sep;4(9):54-61.

Del Rosso JQ, Levin J. The clinical relevance of maintaining the functional integrity of the stratum corneum in both healthy and disease-affected skin. *J Clin Aesthet Dermatol.* 2011 Sep;4(9):22-42.

Del Rosso JQ, Bhatia N. Azelaic acid gel 15% in the management of papulopustular rosacea: a status report on available efficacy data and clinical application. *Cutis.* 2011 Aug;88(2):67-72.

Ritvo E, Del Rosso JQ, Stillman MA, La Riche C. Psychosocial judgements and perceptions of adolescents with acne vulgaris: A blinded, controlled comparison of adult and peer evaluations. *Biopsychosoc Med.* 2011 Aug 13;5(1):11.

Del Rosso JQ. Management of papulopustular rosacea and perioral dermatitis with emphasis on iatrogenic causation or exacerbation of inflammatory facial dermatoses: use of doxycycline-modified release 40 mg capsule once daily in combination with properly selected skin care as an effective approach. *J Clin Aesthet Dermatol.* 2011 Aug;4(8):20-30.

Del Rosso JQ. Current regimens and guideline implications for the treatment of actinic keratosis: proceedings of a clinical roundtable at the 2011 Winter Clinical Dermatology Conference. *Cutis.* 2011 Jul;88(1):suppl 1-8.

Del Rosso JQ. Repair and maintenance of the epidermal barrier in patients diagnosed with atopic dermatitis: an evaluation of the components of a body wash-moisturizer skin care regimen directed at management of atopic skin. *J Clin Aesthet Dermatol.* 2011 Jun;4(6):45-55.

Bellew S, Thiboutot D, Del Rosso JQ. Pathogenesis of acne vulgaris: what's new, what's interesting and what may be clinically relevant. *J Drugs Dermatol.* 2011 Jun;10(6):582-5.

Del Rosso JQ. Adult seborrheic dermatitis: a status report on practical topical management. *J Clin Aesthet Dermatol.* 2011 May;4(5):32-8.

Kircik LH, Del Rosso JQ, Aversa D. Evaluating clinical use of a ceramide-dominant, physiologic lipid-based topical emulsion for atopic dermatitis. *J Clin Aesthet Dermatol.* 2011 Mar;4(3):34-40.

Kim GK, Del Rosso JQ. Status report on the management of dermatofibrosarcoma protuberans: is there a viable role for the use of imatinib mesylate? In which cases may it be therapeutically helpful and in which cases not? *J Clin Aesthet Dermatol.* 2011 Mar;4(3):17-26.

Del Rosso JQ. Wound care in the dermatology office: where are we in 2011? *J Am Acad Dermatol.* 2011 Mar;64(3 Suppl):S1-7.

Leyden JJ, Del Rosso JQ. Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives. *J Clin Aesthet Dermatol.* 2011 Feb;4(2):40-7.

Del Rosso JQ. Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial. *Cutis.* 2010 Nov;86(5 Suppl):16-25.

Zeichner JA, Lebwohl MG, Menter A, Bagel J, Del Rosso JQ, Elewski BE, Feldman SR, Kircik LH, Koo J, Gold LS, Tanghetti E; Psoriasis Process of Care Consensus Panel. Optimizing topical therapies for treating psoriasis: a consensus conference. *Cutis*. 2010 Sep;86(3 Suppl):5-31.

Del Rosso JQ, Pillai R, Moore R. Absence of degradation of tretinoin when benzoyl peroxide is combined with an optimized formulation of tretinoin gel (0.05%). *J Clin Aesthet Dermatol*. 2010 Oct;3(10):26-8.

Kim GK, Del Rosso JQ. The rationale behind topical vitamin D analogs in the treatment of psoriasis: where does topical calcitriol fit in? *J Clin Aesthet Dermatol*. 2010 Aug;3(8):46-53.

Kim GK, Del Rosso JQ. Laser and light-based therapies for acne vulgaris: a current guide based on available data. *J Drugs Dermatol*. 2010 Jun;9(6):614-21.

Momin SB, Peterson A, Del Rosso JQ. A status report on drug-associated acne and acneiform eruptions. *J Drugs Dermatol*. 2010 Jun;9(6):627-36.

Del Rosso JQ, Bruce S, Jarratt M, Menter A, Staedtler G. Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. *J Drugs Dermatol*. 2010 Jun;9(6):607-13.

Tanghetti E, Dhawan S, Green L, Del Rosso J, Draelos Z, Leyden J, Shalita A, Glaser DA, Grimes P, Webster G, Barnett P, Le Gall N. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. *J Drugs Dermatol*. 2010 May;9(5):549-58.

J Clin Aesthet Dermatol. 2010 Apr;3(4):49-54.

Kim GK, Del Rosso JQ. The risk of fluoroquinolone-induced tendinopathy and tendon rupture: what does the clinician need to know? *J Clin Aesthet Dermatol*. 2010 Apr;3(4):49-54.

Kircik L, Del Rosso JQ. Comparative efficacy and safety results of topical hemostatic powder and sterile compressed foam sponge in second intention healing following Mohs micrographic surgery. *J Drugs Dermatol*. 2010 Feb;9(2):137-40.

Kim GK, Del Rosso JQ. Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance. *J Clin Aesthet Dermatol*. 2010 Jan;3(1):32-8.

Del Rosso JQ, Schmidt NF. A review of the anti-inflammatory properties of clindamycin in the treatment of acne vulgaris. *Cutis*. 2010 Jan;85(1):15-24.

Michaels BD, Del Rosso JQ, Momin SB. Avoiding the legal "blemish": medicolegal pitfalls in dermatology. *J Clin Aesthet Dermatol*. 2009 Dec;2(12):35-43.

Del Rosso JQ. Perspectives on seborrheic dermatitis: looking back to move ahead. *Clin Dermatol*. 2009 Nov-Dec;27(6 Suppl):S39-40.

Kim GK, Del Rosso JQ. Seborrheic dermatitis and *Malassezia* species: how are they related. *J Clin Aesthet Dermatol*. 2009 Nov;2(11):14-7.

Bellew S, Del Rosso JQ, Kim GK. Skin cancer in asians: part 2: melanoma. *J Clin Aesthet Dermatol*. 2009 Oct;2(10):34-6.

Del Rosso JQ, Kim GK. Topical antibiotics: therapeutic value or ecologic mischief? *Dermatol Ther*. 2009 Sep-Oct;22(5):398-406.

Del Rosso JQ, Bhambri S. Daily application of fluocinonide 0.1% cream for the treatment of atopic dermatitis. *J Clin Aesthet Dermatol*. 2009 Sep;2(9):24-32.

Kim GK, Del Rosso JQ, Bellew S. Skin cancer in asians: part 1: nonmelanoma skin cancer. *J Clin Aesthet Dermatol*. 2009 Aug;2(8):39-42.

Bellew S, Del Rosso JQ, Mobini N. Primary carcinosarcoma of the ear: case report and review of the literature. *J Clin Aesthet Dermatol*. 2009 Aug;2(8):33-5.

Del Rosso JQ. The use of moisturizers as an integral component of topical therapy for rosacea: clinical results based on the Assessment of Skin Characteristics Study. *Cutis*. 2009 Aug;84(2):72-6.

Del Rosso JQ. A 6% benzoyl peroxide foaming cloth cleanser used in the treatment of acne vulgaris: aesthetic characteristics, patient preference considerations, and impact on compliance with treatment. *J Clin Aesthet Dermatol*. 2009 Jul;2(7):26-9.

Del Rosso JQ. Anti-inflammatory dose doxycycline in the treatment of rosacea. *J Drugs Dermatol*. 2009 Jul;8(7):664-8.

Thiboutot DM, Fleischer AB, Del Rosso JQ, Rich P. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. *J Drugs Dermatol*. 2009 Jul;8(7):639-48.

Thiboutot D, Eichenfield L, Shalita A, Del Rosso JQ, Swinyer L, Tanghetti E, Tschene E, Parr LA. 3-step acne system containing solubilized benzoyl peroxide versus clindamycin-benzoyl peroxide. *Cutis*. 2009 Jul;84(1):48-55.

Bhambri S, Del Rosso JQ, Bhambri A. Pathogenesis of acne vulgaris: recent advances. *J Drugs Dermatol*. 2009 Jul;8(7):615-8.

Del Rosso JQ, Baldwin H, Keri J, Mancini A, Gold LS, Webster GF. Current approach to acne management: a community-based analysis. *Cutis*. 2009 Jun;83(6 Suppl):5-21.

Momin SB1, Del Rosso JQ, Michaels B, Mobini N. Acute generalized exanthematous pustulosis: an enigmatic drug-induced reaction. *Cutis*. 2009 Jun;83(6):291-8.

Kircik LH, Del Rosso JQ. Anti-TNF agents for the treatment of psoriasis. *J Drugs Dermatol*. 2009 Jun;8(6):546-59.

Del Rosso JQ, Sofen H, Leshin B, Meng T, Kulp J, Levy S. Safety and efficacy of multiple 16-week courses of topical imiquimod for the treatment of large areas of skin involved with actinic keratoses. *J Clin Aesthet Dermatol*. 2009 Apr;2(4):20-8.

Del Rosso JQ, Lehman PA, Raney SG. Impact of order of application of moisturizers on percutaneous absorption kinetics: evaluation of sequential application of moisturizer lotions and azelaic acid gel 15% using a human skin model. *Cutis*. 2009 Mar;83(3):119-24.

Momin SB, Richardson BS, Bryan MG, Del Rosso JQ, Mobini N. Mycetoma clinically masquerading as squamous cell carcinoma: case report and literature review. *J Clin Aesthet Dermatol*. 2009 Feb;2(2):26-31.

Del Rosso JQ, Kim G. Optimizing use of oral antibiotics in acne vulgaris. *Dermatol Clin*. 2009 Jan;27(1):33-42.

Bhambri S, Bhambri A, Del Rosso JQ. Atypical mycobacterial cutaneous infections. *Dermatol Clin*. 2009 Jan;27(1):63-73.

Del Rosso JQ. Oral antibiotic drug interactions of clinical significance to dermatologists. *Dermatol Clin*. 2009 Jan;27(1):91-4.

Bikowski JB, Del Rosso JQ. Demodex dermatitis: a retrospective analysis of clinical diagnosis and successful treatment with topical crotamiton. *J Clin Aesthet Dermatol*. 2009 Jan;2(1):20-5.

Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: a status report. *Dermatol Clin*. 2009 Jan;27(1):1-15.

Del Rosso JQ. Benzoyl peroxide cleansers for the treatment of acne vulgaris: status report on available data. *Cutis*. 2008 Nov;82(5):336-42.

Del Rosso JQ. Selection of therapy for acne vulgaris: balancing concerns about antibiotic resistance. *Cutis*. 2008 Nov;82(5 Suppl):12-6.

Del Rosso JQ. Update from the Scientific Panel on Antibiotic Use in Dermatology: clinical considerations for the dermatologist. *Cutis*. 2008 Aug;82(2 Suppl 2):3-4.

Del Rosso JQ, Leyden JJ, Thiboutot D, Webster GF. Antibiotic use in acne vulgaris and rosacea: clinical considerations and resistance issues of significance to dermatologists. *Cutis*. 2008 Aug;82(2 Suppl 2):5-12.

Del Rosso JQ. Comprehensive management of patients with superficial fungal infections: the role of sertaconazole nitrate. *Cutis*. 2008 Jun;81(6 Suppl):4-18.

Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. *J Drugs Dermatol*. 2008 Jun;7(6):573-6.

Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, Graupe K. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. *J Drugs Dermatol*. 2008 Jun;7(6):541-6.

Del Rosso JQ, Baldwin H, Webster G; American Acne & Rosacea Society. American Acne & Rosacea Society rosacea medical management guidelines. *J Drugs Dermatol*. 2008 Jun;7(6):531-3.

Del Rosso JQ, Jitpraphai W, Bhambri S, Momin S. Clindamycin phosphate 1.2%- tretinoin 0.025% gel: vehicle characteristics, stability, and tolerability. *Cutis*. 2008 May;81(5):405-8.

- Bhambri S, Desai A, Del Rosso JQ, Mobini N. Dermatofibrosarcoma protuberans: a case report and review of the literature. *J Clin Aesthet Dermatol*. 2008 May;1(1):34-6.
- Del Rosso JQ, Baum EW. Comprehensive medical management of rosacea: an interim study report and literature review. *J Clin Aesthet Dermatol*. 2008 May;1(1):20-5.
- Romanowicz M, Stephenson JJ, Del Rosso JQ, Lenhart G. Healthcare utilization and costs of patients with rosacea in an insured population. *J Drugs Dermatol*. 2008 Jan;7(1):41-9.
- Del Rosso JQ. Newer topical therapies for the treatment of acne vulgaris. *Cutis*. 2007 Nov;80(5):400-10.
- Del Rosso JQ. Recently approved systemic therapies for acne vulgaris and rosacea. *Cutis*. 2007 Aug;80(2):113-20.
- Bhambri S, Del Rosso JQ, Desai A. Oral trimethoprim/sulfamethoxazole in the treatment of acne vulgaris. *Cutis*. 2007 Jun;79(6):430-4.
- Del Rosso JQ. Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. *J Drugs Dermatol*. 2007 Jun;6(6):616-22.
- Del Rosso JQ, Bikowski JB, Baum E, Smith J, Hawkes S, Benes V, Bhatia N. A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance. *J Drugs Dermatol*. 2007 Jun;6(6):597-600.
- Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. *Cutis*. 2007 Jun;79(6 Suppl):9-25.
- Del Rosso JQ, Elston DM. Tackling the anterior nares and other sites of colonization: implications for the dermatologist. *Cutis*. 2007 Jun;79(6 Suppl):52-9.
- Del Rosso JQ, Webster GF, Jackson M, Rendon M, Rich P, Torok H, Bradshaw M. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. *J Am Acad Dermatol*. 2007 May;56(5):791-802.
- Del Rosso JQ. The treatment of viral infections and nonmelanoma skin cancers. *Cutis*. 2007 Apr;79(4 Suppl):29-35.
- Desai A, Kartono F, Del Rosso JQ. Systemic retinoid therapy: a status report on optimal use and safety of long-term therapy. *Dermatol Clin*. 2007 Apr;25(2):185-93.
- Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. *Dermatol Clin*. 2007 Apr;25(2):133-41.
- Del Rosso JQ, Leyden JJ. Status report on antibiotic resistance: implications for the dermatologist. *Dermatol Clin*. 2007 Apr;25(2):127-32.
- Del Rosso JQ, Draelos ZD, Jorizzo JL, Joseph WS, Ribotsky BM, Rich P. Modern methods to treat superficial fungal disease. *Cutis*. 2007 Feb;79(2 Suppl):6-29.
- Wolf JE Jr, Del Rosso JQ. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. *Cutis*. 2007 Jan;79(1):73-80.
- Del Rosso JQ. Defining criteria used to evaluate response to treatment of acne vulgaris. *Cutis*. 2006 Aug;78(2):117-21.

- Del Rosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. *Cutis*. 2006 Aug;78(2):97-100.
- Del Rosso JQ. Combination topical therapy in the treatment of acne. *Cutis*. 2006 Aug;78(2 Suppl 1):5-12.
- Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. *Int J Dermatol*. 2006 May;45(5):489-98.
- Del Rosso JQ. Clinical significance of brand versus generic formulations: focus on oral minocycline. *Cutis*. 2006 Mar;77(3):153-6.
- Del Rosso JQ. The use of topical azelaic acid for common skin disorders other than inflammatory rosacea. *Cutis*. 2006 Feb;77(2 Suppl):22-4.
- Del Rosso JQ, Tanghetti E. The clinical impact of vehicle technology using a patented formulation of benzoyl peroxide 5%/clindamycin 1% gel: comparative assessments of skin tolerability and evaluation of combination use with a topical retinoid. *J Drugs Dermatol*. 2006 Feb;5(2):160-4.
- Del Rosso JQ. The use of topical imiquimod for the treatment of actinic keratosis: a status report. *Cutis*. 2005 Oct;76(4):241-8.
- Del Rosso JQ. A qualitative and quantitative assessment of the application and use of topical acne medication by patients. *Cutis*. 2005 Aug;76(2):109-13.
- Del Rosso JQ, Bikowski J. Topical metronidazole combination therapy in the clinical management of rosacea. *J Drugs Dermatol*. 2005 Jul-Aug;4(4):473-80.
- Del Rosso JQ. Antibiotic resistance: overview and significance in dermatology. *Cutis*. 2005 Apr;75(4 Suppl):12-8.
- Del Rosso JQ. Adjunctive skin care in the management of rosacea: cleansers, moisturizers, and photoprotectants. *Cutis*. 2005 Mar;75(3 Suppl):17-21.
- Del Rosso JQ. A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effects of the tetracyclines. *Cutis*. 2004 Aug;74(2):118-22.
- Del Rosso JQ. Medical treatment of rosacea with emphasis on topical therapies. *Expert Opin Pharmacother*. 2004 Jan;5(1):5-13.
- Del Rosso JQ. Evaluating the role of topical therapies in the management of rosacea: focus on combination sodium sulfacetamide and sulfur formulations. *Cutis*. 2004 Jan;73(1 Suppl):29-33.
- Del Rosso JQ. New and emerging topical approaches for actinic keratoses. *Cutis*. 2003 Oct;72(4):273-6, 279.
- Del Rosso JQ. Oral cephalosporin antibiotics: an overview of clinical pharmacology and dermatologic applications. *Cutis*. 2003 Feb;71(2):153-7.
- Del Rosso JQ. An update on newer topical therapies for actinic keratoses: advances and applications. *J Drugs Dermatol*. 2003 Jan;2(1):35-9.
- Del Rosso JQ. Cephalosporins in dermatology. *Clin Dermatol*. 2003 Jan-Feb;21(1):24-32.

Del Rosso JQ. A status report on the medical management of rosacea: focus on topical therapies. *Cutis*. 2002 Nov;70(5):271-5.

Del Rosso JQ. Retinoic acid receptors and topical acne therapy: establishing the link between gene expression and drug efficacy. *Cutis*. 2002 Aug;70(2):127-9.

Del Rosso JQ. Skin manifestations of drug reactions. *Curr Allergy Asthma Rep*. 2002 Jul;2(4):282-7.

Del Rosso JQ. Systemic therapy for rosacea: focus on oral antibiotic therapy and safety. *Cutis*. 2000 Oct;66(4 Suppl):7-13.

Del Rosso JQ. Current management of onychomycosis and dermatomycoses. *Curr Infect Dis Rep*. 2000 Oct;2(5):438-445.

Gupta AK, Del Rosso JQ. An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents. *Int J Dermatol*. 2000 Jun;39(6):401-11.

Del Rosso JQ, Gupta AK. The use of intermittent itraconazole therapy for superficial mycotic infections: a review and update on the 'one week' approach. *Int J Dermatol*. 1999 Sep;38 Suppl 2:28-39.

Del Rosso JQ, Gupta AK. Management of tinea capitis. A status report. *Postgrad Med*. 1999 Jul;Spec No:38-45.

Gupta AK, Chang P, Del Rosso JQ, Adam P, Hofstader SL. Onychomycosis in children: prevalence and management. *Pediatr Dermatol*. 1998 Nov-Dec;15(6):464-71.

Del Rosso JQ, Zellis S, Gupta AK. Itraconazole in the treatment of superficial cutaneous and mucosal *Candida* infections. *J Am Osteopath Assoc*. 1998 Sep;98(9):497-502.

Gupta AK, Del Rosso JQ, Lynde CW, Brown GH, Shear NH. Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. *Clin Exp Dermatol*. 1998 Mar;23(2):64-7.

Del Rosso JQ. Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis. *J Am Osteopath Assoc*. 1997 Jun;97(6):339-46.

Del Rosso JQ. Treatment of onychomycosis and tinea pedis with intermittent itraconazole therapy. *J Am Osteopath Assoc*. 1996 Oct;96(10):607-9.

Geiss DF, Del Rosso JQ, Murphy J. Verruciform xanthoma of the glans penis: a benign clinical simulant of genital malignancy. *Cutis*. 1993 May;51(5):369-72.

Del Rosso JQ. Treatment of Darier's disease with isotretinoin: report of a case. *J Am Osteopath Assoc*. 1986 Oct;86(10):634-8.